

Analytical Method Development and Validation of RP-HPLC for The Quantitative Determination of Baricitinib in Pure Substances and Marketed Formulation

Santhosh Illendula* and Peddaboina Shiva Prasad

*Associate Professor, Department of Pharmaceutical Analysis, Nalanda College of Pharmacy, Charlapally, Nalgonda, Telangana – 508001.

Received: 22 Mar 2022 / Accepted: 20 Apr 2022 / Published online: 1 Jul 2022 *Corresponding Author Email: santoshillendula@gmail.com


Abstract

An accurate, precise and rapid RP-HPLC method was developed and subsequently validated for the determination of Baricitinib in bulk form and marketed pharmaceutical dosage form. Better separation of the drug was achieved on Develosil ODS HG-5 RP C18, 5 μ m, 15cmx4.6mm i.d. with the mobile phase consisted of mixture of Methanol and Phosphate buffer (0.02M, pH-3.6) in ratio of 45:55v/v at flow rate of 1.0ml/min, with detection at 255nm using UV detector. The retention time was found to be 3.254min. The method was found to be linear in the range of 12-28 μ g/ml with a correlation coefficient (r2) of 0.9995. The LOD and LOQ of the method were calculated to be 5.004 and 15.164 μ g/ml respectively. The Precision was estimated by employing repeatability; intra-day and inter-day studies and the results were calculated as %RSD values and were found to be within the limits. Recovery of Baricitinib was found to be in the range of 98-102-% which confirms the accuracy of the method. The proposed HPLC method is validated using standard ICH guidelines.

Keywords

Baricitinib, RP-HPLC, Method Development, Accuracy, Precision, ICH Guidelines.

INTRODUCTION: Baricitinib The Chemical Formula is C₁₆H₁₇N₇O₂S. 371.42g/mol: Molecular Weight Structure





2- [1-ethyl sulfonyl-3-[4-(7H-pyrrolo [2, 3-d]] **IUPAC Nomenclature** pyrimidin-4-yl) pyrazol-1-yl] azetidin-3-yl] acetonitrile

Mechanism of Activation: Janus kinases (JAKs) are intracellular enzymes that regulate cytokine and growth factor receptor signals during hematopoiesis, inflammation, and immune cell activity. They belong to the tyrosine kinase family. When cyto-kines & progress influences drag to JAKs, they phosphorrylate & trigger Pointer Trans-ducers & Activ-ators of Transcript (STATs). STATs control intra/cellular activity, together with gene transcription of inflammatory mediators such as IL-2, IL-6, IL-12, IL-15, IL-23, IFN-, GM-CSF, and interferons, all of which cause an autoimmune response. The JAK-STAT pathway, which is associated to inflammatory mediator overproduction, takes been allied to the pathogenesis of rheumatoid arthritis.

MATERIALS AND METHODS:

Chemicals and Reagents: Methanol, Ethanol, Acetone, Dimethyl sulphoxide, Phosphate buffer. **Instruments:**

Waters HPLC with Empower software, Electronic Balance (CITIZEN BALANCE BL-220H), Ultra Sonicator (ANALYTICAL), and P^H Analyzer (ELICO), Distillation unit (BOROSIL), Vaccum filtration unit (BOROSIL). Reagents and Solutions Selection of Wavelength The standard & sample stock solutions were prepared separately by dissolving standard & sample in a solvent in mobile phase diluting with the same solvent. (After optimization of all conditions) for UV analysis. It scanned in the UV spectrum in the range of 200 to 400nm. This has been performed to know the maxima of Baricitinib, so that the same wave number can be utilized in HPLC UV detector for estimating the Baricitinib.

Preparation of Standard and Sample Solutions

25 mg of Baricitinib standard was transferred into 25 ml volumetric flask, dissolved & make up to volume with mobile phase. Further dilution was done by transferring 0.3 ml of the above solution into a 10 ml volumetric flask and make up to volume with mobile phase.

Preparation of 0.02M Potassium di hydrogen orthophosphate Solution

About 2.72172grams of Potassium di hydrogen orthophosphate was weighed and transferred into a 1000ml beaker, dissolved, and diluted to 1000ml with HPLC Grade water. The pH was adjusted to 2.80 with diluted ortho phosphoric acid Solution.

Preparation of Mobile Phase


550 mL (55%) of above Phosphate buffer solution and 450 mL of Methanol (45%) were mixed well and degassed in ultrasonic water bath for 15 minutes. The resulted solution was filtered through 0.45 μm filter under vacuum filtration.

METHOD VALIDATION Method Optimization:

Mobile phase	Methanol : Phosphate buffer (0.02M, pH-3.6) = 45:55
Column	Develosil ODS HG-5 RP C ₁₈ , 5µm, 15cmx4.6mm i.d.
Column Temperature	Ambient
Detection Wavelength	255 nm
Flow rate	1.0 ml/ min.
Run time	07 min.
Temperature of Auto sampler	Ambient
Diluent	Mobile Phase
Injection Volume	20µ1
Type of Elution	Isocratic

109






Optimized Chromatographic Condition

Results of Optimized Chromatogram

S. No.	Drug Name	RT	Peak Area	Theoretical Plates	Tailing Factor
1	Baricitinib	3.254	283261	7258	1.25

RESULTS AND DISCUSSION:



ſ



Linearity Readings for Baricitinib

Encounty neodalings for Barretening			
CONC.(µg/ml)	MEAN AUC		
	(n=6)		
0	0		
12	690316		
16	910621		
20	1121057		
24	1328903		
28	1554666		

Table-1: Results of accuracy: Accuracy outcomes of Baricitinib

	Concentration (µg/ml)		%Recovery		
Sample ID	Conc.	Conc.	Peak Area	of	Statistical Analysis
	Found	Recovered		Pure drug	
S1:80 %	8	8.064107	458679	99.867	Mean= 100.4113%
S ₂ : 80 %	8	7.843532	446485	100.637	S.D. = 0.473694346
S ₃ : 80 %	8	8.19449	465887	100.73	% R.S.D.= 0.471753
S ₄ : 100 %	10	9.892661	559767	99.41	Mean= 100.6646667%
S ₅ : 100 %	10	9.978655	564521	100.868	S.D. = 1.166369295
S ₆ : 100 %	10	10.19623	576549	101.716	R.S.D.= 1.158667
S ₇ : 120 %	12	11.85907	668476	99.878	Mean= 100.4637%
S ₈ : 120 %	12	12.16785	685546	100.69	S.D. = 0.51154309
S ₉ : 120 %	12	12.18644	686574	100.823	% R.S.D. = 0.509181

2. Precision: **Repeatability Results of Baricitinib**

HPLC Injection Replicates	AUC for Baricitinib
Replicate – 1	285479
Replicate – 2	284571
Replicate – 3	286954
Replicate – 4	283261
Replicate – 5	285964
Replicate – 6	284259
Average	285081.3
Standard Deviation	1318.666
% RSD	0.462558

P



ii) Intermediate Precision / Ruggedness

	Ruggedness Results for Baricitinib					
Conc. of	Observed Conc. of Baricitinib (µg/ml) by the proposed method					
Baricitinib (API) (µg/ml)	Intra-Day Inter-Day					
	Mean (n=3)	% RSD	Mean (n=3)	% RSD		
8	8.21	0.76	8.23	0.46		
10	10.37	0.33	10.36	0.57		
12	12.56	0.23	12.56	0.75		

Ruggedness Results for Baricitinib

Robustness:

Consequence of Technique Toughness

Change in Parameter	% RSD
Flow (0.8 ml/min)	0.554
Flow (1.2 ml/min)	0.867
More Organic	0.886
Less Organic	0.817
Wavelength of Detection (257 nm)	0.813
Wavelength of detection (253 nm)	0.794

LOD: For Baricitinib, the LOD was determined to be 5.004g/ml.

LOQ: The LOQ for Baricitinib was discovered to be 15.164g/ml.

Assay:

Retrieval Statistics for Assessment Baricitinib in Olumiant Tablets

Brand Name of	Labelled amount	Mean (± SD) amount (mg)	Assay %
Baricitinib	of Drug (mg)	found by the proposed method	(1.670)
		(n=6)	(± SD)
Olumiant Tablet (Lilly)	4mg	3.896 (± 0.867)	99.698 (±
			0.476)

D



Stress Condition	Time	Assay of active	Assay of degraded	Mass
	(hours)	substance	products	Balance (%)
Acid Hydrolysis (0.1N HCl)	24Hrs.	91.326	8.674	100.00
Basic Hydrolysis (0.IN NaOH)	24Hrs.	83.215	16.785	100.00
Thermal Degradation (60 ⁰ C)	24Hrs.	90.311	9.689	100.00
UV (254nm)	24Hrs.	81.322	18.678	100.00
3% Hydrogen Peroxide	24Hrs.	73.514	26.486	100.00

FORCED DEGRADATION STUDIES **Consequences of Enforced Deprivation**

CONCLUSION:

This study created a simple, quick, efficient, and reliable RP-HPLC method for assessing Baricitinib in bulk medication and pharmaceutical dosage forms. This procedure was straightforward since diluted samples were employed immediately without any chemical derivatization or purification. The travelling segment was a 45:55 percent v/v mixture of methanol and phosphate buffer. This procedure's solvent system was proved to be cost-effective. The approach was validated, and the percent RSD results were accurate to within a factor of two. The RP-HPLC technique yielded good results, as shown in the tables. Spectrophotometric technologies are less sensitive, accurate, and precise than RP-HPLC technology. This approach might be used on a regular basis to assess the concentration of Baricitinib in bulk medicine and pharmaceutical dosage forms.

ACKNOWLEDGEMENT:

The authors are grateful to the management of Nalanda College of Pharmacy, Nalgonda for providing the facilities to carry out the present research work

REFERENCES:

- 1. Instrumental Analysis, Skoog, Fifth edition, Page no. 312-316.
- 2. Instrumental methods of chemical analysis, Gurdeep R. Chatwal. Page no2.116-2.122.
- 3. Elementary organic analysis, Principles and chemical applications, YR Sharma, page no12-14.
- 4. A textbook of pharmaceutical analysis, Kasturi A V, Vol 3 10th ed., 169-81.
- 5. Willard-Hobart H, Merritt Jr Lynne L, Dean John A (1974) Instrumental Methods of Analysis. (5thedn), Von Nostrand, University of Michigan.

- 6. Chatwal GR, Anand S (2002) Instrumental Methods of Chemical Analysis. (5thedn), Himalaya Publishing House, New Delhi.
- 7. Davidson AG (2002) Ultraviolet-visible absorption Spectrophotometry. In Beckett AH, Stenlake JB, (4thedn), Practical Pharmaceutical chemistry. CBS Publishers and distributors, New Delhi, 275-278.
- 8. Robert AN, Pharmaceutical process validation, publisher Marcel Dekker, Inc, 2003; 507-522.
- 9. Text on Validation of Analytical Procedures Q2A in; I.C.H. Harmonized Tripartite Guidelines, Oct. 1994.
- 10. Text on Validation of Analytical Procedures Q2B in; I.C.H. Harmonized Tripartite Guidelines, Nov. 1996.
- 11. Indian Pharmacopoeia 2014, published by the Indian Pharmacopeia commission Ghaziabad: 2191-2194.
- 12. USP NF, The Official Compendia of Standards, Asian edition. 2008, 2662-2663.
- 13. British Pharmacopeia 2004 amended by supplements, 4.1-4.8 inclusive: 2577.
- 14. Wegscheider, Validation of Analytical Methods, in: Accreditation and Quality Assurance in Analytical Chemistry, H. Guenzler, Springer (Ed.) Verlag and Berlin 1996.
- 15. Validation of Analytical Procedures: Text and Methodology, ICH Harmonized Tripartite Guideline. Q2 (R1), International Conference on Harmonization, Geneva, 2005, 1-13.
- 16. L.A. Woodward, Introduction to the Theory of Molecular Vibration and Vibrational Spectroscopy, Oxford University Press, London, 1972.
- 17. W.A. Guillory, Introduction to Molecular Structure and Spectroscopy, Allyn and Baccon Inc., Boston, 1977.
- 18. G. Herzberg, Infrared and Raman Spectra of Polyatomic Molecules, Van Nostrand, New York, 1964.
- 19. N.B. Colthup, L.H. Daly, S.E. Wiberely, Introduction to Infrared and Raman Spectroscopy, Academic press, New York, 1964.
- 20. G.F. Dyke, A.J. Floyd, M. Sainsbyrg, R.S. Theobald, Organic Spectroscopy: An Introduction, Longman Inc., New York, 1981.



- 21. D.N. Sathyanarayana, Vibrational Spectroscopy Theory and Application, New Age International publishers, New Delhi, 2004.
- R.E. Dpdd. Chemical Spectroscopy, Elsevier Publishing Company, New York, 1962. [10] S.D. Ross, Inorganic Infrared and Raman spectra, Mc Graw-Hill, London, 1972.
- 23. https://go.drugbank.com/drugs/DB11817
- 24. https://pubchem.ncbi.nlm.nih.gov/compound/Bariciti nib
- 25. https://en.wikipedia.org/wiki/Baricitinib
- 26. Santhosh Illendula, Naveen kumar singhal (2022), Novel analytical method development and validation for the determination of selected anti cancer and anti viral drugs. World journal of pharmacy and Pharmaceutical Sciences Volume 11, Issue 7, 553-566.
- 27. Santhosh Illendula, Muthyam sanjana (2019), A validated stability indicating RP-HPLC method development for the estimation of pomalidomide in bulk and pharmaceutical dosage form. International journal of pharmacy and biological sciences Volume 09, Issue 1, 63-72.

- Mannurkar M. M.*, Hamrapurkar P. D., Development and Validation of RP- HPLC Method for Baricitinib using Quality by Design Approach and its Application to Stability Studies, IJPQA, Volume 12, Issue 1, January 2021 – March 2021, Pages: 40-47.
- 29. S. Mohan, N. Srinivasarao, K. Lakshmi, Development and Validation of a Stability indicating Related Substances of Baricitinib by RP-HPLC and its Degradation, International Journal of Management and Humanities (IJMH), ISSN: 2394-0913 (Online), Volume-4 Issue-2, October 2019, DOI:10.35940/ijmh.A0369.10 4219.
- 30. Shanaz Begum1*, V. Ravi Kumar1, Ramya Sri2, Method Development and Validation for Determination of Baricitinib in Pure Form and Marketed Pharmaceutical Dosage Form by RP-HPLC, High Technology Letters, Volume 28, Issue 4, 2022, Pages: 309-325.
- 31. Badithala Siva Sai Kiran*, Sundararajan Raja, RP-HPLC Method Development and Validation for the Quantification of Tofacitinib, Research Journal of Life Sciences, Bioinformatics, Pharmaceutical and Chemical Sciences, 2018, July-August, RJLBPCS 4(4), Page No: 646.

114